Active Ingredient(s): Tafenoquine
FDA Approved: * July 20, 2018
Category: Malaria

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Krintafel Overview

Tafenoquine, sold under the brand name Krintafel, is an 8-aminoquinoline drug manufactured by GlaxoSmithKline as a treatment for malaria, as well as for malaria prevention.[2][3] The indication for tafenoquine is for treatment of the hypnozoite stages of Plasmodium vivax and Plasmodium ovale that are responsible for relapse of these malaria species even when the blood stages are successfully cleared. This is only now achieved by administration of daily primaqui...

Read more Krintafel Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Krintafel Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 100mg, 150mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Krintafel: (1 result)

Sorted by National Drug Code
  • 0173-0889 Krintafel 150 mg Oral Tablet, Film Coated by Glaxosmithkline LLC

Other drugs which contain Tafenoquine or a similar ingredient: (2 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 13 October 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA